TR201820051T4 - Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması - Google Patents

Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması Download PDF

Info

Publication number
TR201820051T4
TR201820051T4 TR2018/20051T TR201820051T TR201820051T4 TR 201820051 T4 TR201820051 T4 TR 201820051T4 TR 2018/20051 T TR2018/20051 T TR 2018/20051T TR 201820051 T TR201820051 T TR 201820051T TR 201820051 T4 TR201820051 T4 TR 201820051T4
Authority
TR
Turkey
Prior art keywords
factor
antibodies
prevention
treatment
thrombus formation
Prior art date
Application number
TR2018/20051T
Other languages
English (en)
Inventor
Hack Erik
Original Assignee
Prothix Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40933725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201820051(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prothix Bv filed Critical Prothix Bv
Publication of TR201820051T4 publication Critical patent/TR201820051T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Mevcut buluş, özgül olarak plazma koagülasyon faktörü XI'e bağlanan ve faktör XI aktivasyonunu ve/veya aktivitesini önleyen antikorlar gibi bağlayıcı moleküllerle ilgilidir. Buluşun faktör XI-bağlayıcı molekülleri, faktör XI aktivasyonunun aracılık ettiği hastalıkların, rahatsızlıkların ve/veya durumların engellenmesi veya tedavi edilmesi için ve/veya faktör XI'in önlenmesinin faydalı bir etkiye sahip olduğu yöntemlerde kullanılabilir.
TR2018/20051T 2008-06-19 2009-06-19 Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması TR201820051T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7388208P 2008-06-19 2008-06-19

Publications (1)

Publication Number Publication Date
TR201820051T4 true TR201820051T4 (tr) 2019-01-21

Family

ID=40933725

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/20051T TR201820051T4 (tr) 2008-06-19 2009-06-19 Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması

Country Status (9)

Country Link
US (4) US20110159006A1 (tr)
EP (1) EP2297207B1 (tr)
DK (1) DK2297207T3 (tr)
ES (1) ES2702365T3 (tr)
HR (1) HRP20181727T1 (tr)
HU (1) HUE041556T2 (tr)
PL (1) PL2297207T3 (tr)
TR (1) TR201820051T4 (tr)
WO (1) WO2009154461A1 (tr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160046728A1 (en) * 2007-10-31 2016-02-18 Bioxodes Sa Identification and molecular characterisation of proteins, expressed in the ixodes ricinus salivary glands
PT3002298T (pt) 2007-11-21 2019-11-20 Univ Oregon Health & Science Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos
PL2373691T3 (pl) 2008-12-18 2019-07-31 Oregon Health & Science University PRZECIWCIAŁA ANTY-fXI I SPOSOBY ZASTOSOWANIA
CN103459427B (zh) * 2011-02-01 2018-03-30 Bac Ip私人有限公司 针对人IgG抗体的CH1结构域中表位的抗原结合蛋白
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
LT2847228T (lt) * 2012-05-10 2018-11-12 Bayer Pharma Aktiengesellschaft Antikūnai, galintys jungtis prie koaguliacijos faktoriaus xi ir (arba) jo aktyvuotos formos faktoriaus xia, ir jų panaudojimas
WO2016020880A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
US20180216094A1 (en) * 2015-07-23 2018-08-02 The Regents Of The University Of California REVERSAL AGENTS FOR FXIa INHIBITORS
US11066481B2 (en) * 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
JOP20170013B1 (ar) 2016-01-22 2021-08-17 Merck Sharp & Dohme أجسام xi مضادة لعامل مضاد للتجلط
EP3433279A1 (en) * 2016-03-23 2019-01-30 Prothix BV Monoclonal antibodies against the active site of factor xi and uses thereof
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
PE20190416A1 (es) 2016-06-14 2019-03-19 Merck Sharp & Dohme Anticuerpos antifactor de la coagulacion xi
US11168147B2 (en) * 2016-12-23 2021-11-09 Novartis Ag Factor XI antibodies and methods of use
WO2018116267A2 (en) 2016-12-23 2018-06-28 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
WO2020029179A1 (en) * 2018-08-09 2020-02-13 Shanghai Benemae Pharmaceutical Corporation Anti-factor xi antibodies
US11958911B2 (en) * 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
KR20200087236A (ko) 2017-11-22 2020-07-20 노파르티스 아게 항-인자 XI/XIa 항체에 대한 반전 결합제 및 이의 용도
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437864A (en) * 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
AU3221793A (en) * 1991-11-22 1993-06-15 Scripps Research Institute, The Factor x-derived polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting inflammation
GB9224888D0 (en) * 1992-11-27 1993-01-13 Univ Singapore Monoclonal antibody
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US6500660B1 (en) * 1996-11-27 2002-12-31 Université Catholique de Louvain Chimeric target molecules having a regulatable activity
EP1001991A4 (en) * 1997-07-03 2005-01-26 Smithkline Beecham Corp CRYSTALLINE STRUCTURES OF FAB ANTI-FACTOR IX FRAGMENTS AND METHODS OF USE FOR PEPTIDOMIMETIC DESIGN
US20030143225A1 (en) * 2001-03-08 2003-07-31 Genentech, Inc. Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents
US7371849B2 (en) * 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
ATE529530T1 (de) * 2001-11-05 2011-11-15 Univ Texas Rekombinante antikörper zum nachweis und zur neutralisierung von milzbrandtoxin
US20080219998A1 (en) * 2001-12-07 2008-09-11 Andras Gruber Anti-Thrombotic Agents
US7579000B2 (en) * 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
US20040180855A1 (en) * 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
JP2007501844A (ja) * 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
EP1706079B1 (en) * 2003-08-14 2013-02-20 ThromboGenics N.V. Antibodies against factor viii with modified glycosylation in the variable region
PT3002298T (pt) * 2007-11-21 2019-11-20 Univ Oregon Health & Science Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3433279A1 (en) * 2016-03-23 2019-01-30 Prothix BV Monoclonal antibodies against the active site of factor xi and uses thereof

Also Published As

Publication number Publication date
US8568724B2 (en) 2013-10-29
PL2297207T3 (pl) 2019-03-29
DK2297207T3 (en) 2018-12-03
US20120259097A1 (en) 2012-10-11
WO2009154461A1 (en) 2009-12-23
US20110159006A1 (en) 2011-06-30
EP2297207B1 (en) 2018-10-03
HRP20181727T1 (hr) 2019-02-08
EP2297207A1 (en) 2011-03-23
HUE041556T2 (hu) 2019-05-28
ES2702365T3 (es) 2019-02-28
US20180118850A1 (en) 2018-05-03
US20140194600A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
TR201820051T4 (tr) Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
CY1120102T1 (el) Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
EA200970953A1 (ru) СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
MX2010003095A (es) Antidotos para inhibidores del factor xa y metodos para usar los mismos.
EP2547355A4 (en) TFPI HEMMER AND USE METHOD THEREFOR
EA201001865A1 (ru) Противовоспалительные агенты
TW200730624A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
PH12013500578A1 (en) Substituted dihydropyrazolones for treating cardiovascular and haematological diseases
UA107783C2 (en) Isoindoline compounds for use in treating cancer
EP3722810A3 (en) Molecular profiling of tumors
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
MX2010009724A (es) Procedimientos de tratamiento del dolor inflamatorio-.
ATE456571T1 (de) Proteasom-hemmer und verwendungsverfahren dafür
MY169746A (en) Dual variable domain immunoglobulin and uses thereof
MX2013015158A (es) Compuestos inhibidores de metaloenzima.
AU2011328009A8 (en) Compounds and methods for treating pain
WO2010071894A3 (en) Tfpi inhibitors and methods of use
MX2010009722A (es) Procedimiento de tratamiento del dolor cronico.
WO2009045356A3 (en) Microrna compositions in the treatment of vegf-mediated disorders
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
MX2011006150A (es) Compuestos inhibidores de cinasa.
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
EA201492259A1 (ru) Терапевтические применения фракций мастиковой смолы
WO2008127654A3 (en) Methods and compositions for intra-articular coagulation proteins